Investors''s Presentation
3BBLACKBIO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
3B BlackBio Dx (formerly Kilpest India) shared an investor update covering its Agrochemicals and Molecular Diagnostics (MDx) businesses. Consolidated H1 FY26 revenue rose ~15.5% to Rs 5,613.67 Lakh with PAT up ~5.8% to Rs 2,768.21 Lakh and EPS at Rs 32.31. The MDx division grew ~21% to Rs 5,038.89 Lakh, driven by new products, exports, and the consolidation of Coris Bioconcept SRL (Belgium), which was acquired on Aug 29, 2025 for £2.77 million. Management guided to 15–20% growth for FY26 in India MDx and 20–25% export growth, supported by long-term reagent-rental contracts, new channel partners in Africa/LATAM, and pending global product registrations.
Positive for shareholders on the back of steady revenue and earnings growth, a completed international acquisition expanding the IVD portfolio, and clear forward growth guidance. Watch points: management flagged rising competition putting pressure on margins and a liberal credit policy that has lifted debtor levels, alongside one-time M&A advisory costs weighing on near-term profits.